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Abstract
Purpose of Review This narrative review makes the case for greater efforts to reduce cardiovascular disease (CVD) risk in
women with diabetes.
Recent Findings In a recent meta-analysis including five CVOTs of diabetes medications with 46,606 subjects, women (vs men)
with type 2 diabetes had a higher relative risk for stroke (RR 1.28; 95% CI 1.09, 1.50) and heart failure (1.30; 1.21, 1.40). Prior
studies found higher “within-gender” RR for CVDmortality in women with diabetes although men have an absolute higher risk.
Women with prior gestational diabetes mellitus (GDM) have a 2-fold higher CVD risk than the background population. Worse
CVD and CVD risk factor management in women, as well as lower female therapy adherence, contribute further to these
disparities.
Summary The mechanism behind this excess risk includes biological, hormonal, socioeconomic, clinical, and behavioral factors
that still require further investigation. The need for more intensive CVD reduction in women now includes more attention to
screening for both incident diabetes and CVD risk factors among high-risk women.
Keywords Diabetesmellitus .Gestational diabetes .Cardiovascular disease . Sex .Gender . Prevention .Diabetesmanagement .
CVD risk factors . Lipids . Sex hormones
Introduction
In the general population, women die at an older age than
men in nearly all parts of the world such that life expec-
tancy is on average 4 years higher among women than men
[1]. These differences have been attributed to biological,
socioeconomic, environmental, and behavioral factors
[2–4]. Although women live longer, this advantage fre-
quently fails to translate into increased healthy life years
[5]. Cardiovascular disease (CVD) is the leading cause of
death among both men and women [6]. Diabetes is a well-
known CVD risk factor and thus patients with diabetes
mellitus have a high need for approaches that will reduce
premature mortality from CVD. The number of people
with diabetes worldwide is predicted to increase from the
current 463 million to 700 million by 2045 [7], and with it,
the number of people developing CVD associated with
diabetes. While there are only small gender differences in
the age-specific prevalence of diabetes in adulthood [8••],
there are sex and gender differences in the relationship
between diabetes and CVD mortality.
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Since the Framingham study is nearly five decades ago, it
has been clear that the usual “female protection” is lost among
women with insulin-treated diabetes, and that this is based on
their higher CVD risk [9]. Several other studies subsequently
demonstrated the increased relative risk for CVD in women
with diabetes compared with men, in both type 1 (T1DM) and
type 2 (T2DM) diabetes [10•, 11, 12•, 13••]. An excess CVD
risk has also been shown among women with prior gestational
diabetes mellitus (GDM) [14••]. The exact pathophysiological
explanations remain under-investigated and need further re-
search, but the higher risk seems to be driven by biological,
environmental, and behavioral factors [8••]. Biological causes
discussed include a loss of the protective hormonal effect by
female sex hormones and sex hormone imbalance in hyper-
glycemic conditions leading to higher oxidative stress and
endothelial dysfunction, a proinflammatory environment act-
ing on estrogen receptor actions, a modulation of vascular
response to nitric oxide, and impaired vessel relaxation prop-
erties [8••]. Further proposed explanations for the excess CVD
mortality reported in women with diabetes compared with
those without diabetes include pregnancy-related conditions
and sex and gender differences in diabetes management and
the management of other CVD risk factors [15] including
hypertension [16].
In view of this sex and gender difference in excess CVD
risk, our narrative review poses the question, whether all or, at
least some women with diabetes, are in need of increased and
more aggressive cardiovascular risk reduction than men. This
includes the need for any further advances in diabetes preven-
tion, treatment, CVD risk reduction, or management. We fur-
ther attempt to shed light on the biological and socio-cultural
aspects that are potentially responsible for these sex- and
gender-related disparities.
Why Do Women Live longer?
In general, in high-income populations, life expectancy is 4–
7 years higher in women than in men [17], whereas in low-
income countries, a smaller gap was reported as women have
less access to health care services [1]. Between the poorest and
richest countries, the life expectancy gap opens up to more
than 18 years as reported in a 2018WHO report [1]. There are
some data to suggest that this survival difference is mainly due
to modifiable risk factors with biological causes only playing
a minor role. Key evidence comes from a study comparing
11,000 German male and female cloister inhabitants from
Catholic communities with the general population. A maxi-
mum survival disadvantage of about 1 year of life expectancy
from a young adult age (25 years) was found in the male
cloister inhabitants compared with women from the cloister
communities and the general population [18]. Men from the
general population had a lower life expectancy from a young
adult age compared with the cloister inhabitants. It was also
proposed that these males were unable to decrease their mor-
tality risk, in contrast to the female general population, nuns,
and monks [18]. The protected environment of the cloister
seemed to have positive effects on life expectancy on male
inhabitants. Modifiable risk factors, such as smoking, alcohol,
unhealthy food choices, excess bodyweight, and lack of phys-
ical inactivity, were more prevalent in the male general popu-
lation [18].
While women have longer life expectancy, there is evi-
dence to suggest that the balance between healthy and un-
healthy live years includes a sex-specific imbalance, the so-
called health survival paradox [5]. While women and men
spend comparable time in a “good health” state, the longer
life expectancy in women results in women accumulating
more unhealthy life years compared with men.
Increased Mortality Risk in Women
with Diabetes?
In general, the absolute risk for T2DM and CVD mortality
is higher in men; however, the relative risk of all-cause
and CVD mortality in women with T2DM has consistent-
ly been reported to be significantly higher and was also
reported in women with T1DM (Table 1) [12•, 19, 20,
21•, 22, 23]. Higher risks were observed in younger
groups with diabetes compared with older groups with
the highest risk found in women with diabetes between
35 and 59 years of age [22]. Some studies observed higher
CVD risk in both sexes, with a non-significant higher
relative risk in women [23]. Key findings pertinent to
sex differences in CVD outcomes were the reported
higher obesity, hypertension, and dyslipidemia, as well
as lower prescription of medication among women [23].
Furthermore, the risk of heart failure was reportedly
higher in women with T1DM and T2DM (Table 1) [24•,
25•]. There was a narrowing sex ratio within older age
categories, indicating that relative risk is higher in women
of younger age [24•].
Other studies also hypothesize a reduction in sex-related
protection in women with diabetes, which is, in turn, associ-
ated with higher mortality risk [8••, 27, 28]. Potential risk
factors explaining these differences are shown in Fig. 1. In
view of this substantial effect of diabetes on CVD risk, there
have been discussions over the need for more intensive CVD
reduction activities, and individualization of risk reduction
approaches [8••, 29, 30•]. It is obvious from the presented data
that an individualized risk reduction approach needs to take
into account both sex and age (e.g., the use of CVD risk
reduction agents in women of reproductive age), but there also
needs to be a focus on modifiable risk factors.
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Table 1 Studies reporting sex and gender differences in the effect of diabetes mellitus on all cause and cardiovascular diseasemortality and heart failure
Author Population Design Outcome
Cardiovascular mortality
Xu et al. [19] 2,314,292 individuals, among whom
254,038 all-cause deaths occurred
Systematic review and meta-analysis
including prospective cohort 35
studies
Pooled women vs. men ratio of the HRs
1.17 (95% CI: 1.12–1.23) and 1.97
(1.49–2.61) respectively for all cause
and coronary heart disease (CHD)
mortality.
increased all-cause mortality in men (HR
1.91 (1.72–2.12)) and women (2.33
(2.02–2.69)) with T2DM vs. healthy
population
Wang et al. [20] 5,162,654 participants Systematic review and meta-analysis
including 49 studies
Higher relative all-cause mortality (RRR
1.13, 95% CI 1.07–1.19; p < 0.001)
and CVD mortality (1.30, 1.13–1.49;
p < 0.001) in women with diabetes vs.
men with diabetes.
Women with diabetes vs. men with
diabetes: CHD mortality RRR 1.58,
95% CI 1.32–1.90; p < 0.001 and
stroke mortality 1.08, 1.01–1.15;
p < 0.001
Huxley et al. [21•] 447,064 participants Meta-analysis of 37 prospective cohort
studies
Higher risk of fatal CHD in women with
diabetes vs. men, pooled ratio of the
RR 1.46 (1.14–1.88).
Fatal CHD in patients with diabetes vs.
no diabetes significantly higher in
women than men: 3.50 (2.70–4.53)
vs. 2.06 (1.81–2.34).
Huxley et al. [12•] 214,000 participants and 15,273 events Meta-analysis of 26 studies pooled women-to-men ratio in patients
with T1DM: SMR 1.37 (95% CI
1.21–1.56) for all-cause mortality,
1.44 (1.02–2.05) increased risk for
renal disease mortality, 1.37
(1.03–1.81) for stroke mortality, CVD
mortality 1.86 (1.62–2.15), 2.54







980,793 participants and 76,965
fatalities different ethnicities and age
categories, age 35–89 years
Meta-analysis of 68 prospective studies Doubling of occlusive vascular mortality
risk in men with diabetes RR 2.10,
95% CI 1.97–2.24), tripling in women
with diabetes (3.00, 2.71–3.33) after
stratification for age, total cholesterol,
blood pressure, smoking status and
BMI.
Higher risks in younger groups with
diabetes aged 35–59 years (2.60,
2.30–2.94) vs. older groups aged
70–89 years (2.01, 1.85–2.19),
highest risk in women with diabetes
and age 35 and 59 years (5.55,
4.15–7.44). in absolute numbers,
adjusted diabetes associated excess
occlusive vascular mortality
comparable in men and women across
all age categories
Wright et al. [23] 79,985 patients with incident T2DM
between 2006 and 2013 matched to
386,547 patients without T2DM
Retrospective cohort study Higher CVD event risk in both men and
women, with a non-significant higher
relative risk in women (RR 1.07
(0.98–1.17)
Clemens et al. [13••] 46,606 participants of trials examining
the effect of diabetes medications on
Meta-analysis of 5 CVOTs on 3- or
4-point MACE (i.e., CV death,
Higher risk for women for stroke (RR
1.28; 1.09–1.50), heart failure (1.30;
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Fig. 1 Specific risk factors for progression to CVD and CVD mortality in women with diabetes mellitus
Table 1 (continued)
Author Population Design Outcome
major adverse cardiovascular events
in people ≥18 years of age with
T2DM
nonfatal myocardial infarction,
nonfatal stroke, hospitalization for
heart failure, hospitalization for
unstable angina for 4-point MACE)
1.21–1.40), and CKD (1.33;
1.17–1.51), similar risk for PAD
(1.12; 0.97–1.30) and lower risk for
myocardial infarction (0.71;
0.59–0.86), consistently fewer female
participants (28.5–35.8%) in the trials.
Heart failure
Malmborg et al. [24•] 218,549 (46% women) participants, age
40–89 years
Population based study Higher absolute risk of MACE-HF in
men, but in relative terms 15% higher
women to men ratio (95% Cl
1.11–1.19, p < 0.001) at the age of
50–60 years. The risk of recurrent
CVD events or HF within 30 days
irrespective of diabetes or sex, more
often with increasing age.
Ohkuma et al. [25•]. 12,142,998 individuals and 253,260
heart failure events
Systematic review and meta-analysis of
47 cohorts
Women with diabetes have increased
relative risk of heart failure vs. men:
T1DM (RRR 1.47 (1.44, 1.90)), T2DM
(RRR 1.09 (1.05, 1.13))
Kannel et al. [26]. 5209 men and women, age 30–62 years, Framingham study, 18 year follow up Five- and two-fold increased risk of heart
failure in women and men with
diabetes respectively vs. healthy
population
HR, hazard ratios; RRR, relative risk reduction, defined as the relative decrease in the risk of an event in a cohort exposed compared with a cohort
unexposed to a disease/risk; SMR, standardized mortality ratio, defined as an age and sex matched comparison of mortality in a cohort with a specific
illness to controls; RR, relative risk, defined as the ratio of the likelihood of an event in an exposed compared to an unexposed cohort; CVOT,
cardiovascular outcome trial
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Are the Differences in Excess CVD Mortality
Due to Sex Hormone Differences?
Changes in hormonal action might contribute to the faster
progression of CVD in both men and women with diabetes
as a result of the effects on CVD risk factors as insulin resis-
tance, overweight and obesity, and subsequently hyperglyce-
mia, hypertension, and hypercholesterolemia evolve [31•].
The loss of female protection is therefore potentially driven
by hormonal imbalance with the increased atherogenic lipid
profiles, higher inflammation, or stronger relation of other
CVD risk factors with hyperglycemia in women than men
[8••, 28]. The contribution to the excess CVD among women
with diabetes by pregnancy complications such as gestational
hypertension and preeclampsia are also not fully understood,
but early-onset preeclampsia has been shown to be associated
with risk factors for CVD by the fifth decade of life [32].
Menopause is a particularly important time for CVD
risk factors, when female sex hormone levels (e.g., estro-
gen) suddenly drop associated with a relative increase in
male hormones (e.g., testosterone). This change is associ-
ated with weight gain, impairments in glucose metabolism
and lipid storage, and finally progression to T2DM [8••].
After menopause, lean body mass declines and the preva-
lence of obesity increases [33••, 34]. The low estrogen
levels after menopause reduce total energy expenditure
through effects on the hypothalamus and higher release
of orexigenic hormones [34]. Higher estrogen levels are
also related to increased beta cell function and improved
glycemic control in women with T2DM, and, additionally,
slightly lower T2DM risk was reported in studies adminis-
tering hormone replacement therapy in post-/menopausal
healthy women [35••]. Between the ages of 50 and
59 years, and within 10 years after menopause onset, hor-
mone replacement therapy is effective in preventing the
development of T2DM and cardiovascular disease in wom-
en without diabetes, although safety concerns persist with
the need to balance benefits with risks [35••]. Endogenous
estrogen in women might exert vasoprotective effects and
thus lower cardiovascular events in women—a benefit
which seems attenuated in women with hyperglycemia
[8••, 31•].
Female sex hormones and especially endogenous estrogen
seem to have beneficial and protective effects on islet cells by
preventing islet cell apoptosis driven by oxidative stress and
lipotoxicity [36]. Higher insulin production and secretion
were found along with approximately 6% higher beta cell
content in pancreatic biopsies of women compared with
men. Higher insulin secretion in women was associated with
sex differences in glucagon-like peptide-1 (GLP-1) secretion,
which was found to be 20% higher in normo-glucose-tolerant
women compared with healthy men [36]. These differences
found between women and men did not exist after progression
to prediabetes or diabetes, independent of weight or age sug-
gesting loss of protective effect with progression to diabetes
[36].
An ambivalent role has been described for testosterone.
High testosterone levels in women are associated with insulin
resistance, hyperglycemia, and central obesity as well as hy-
pertension [2, 35••]. Paradoxically, low testosterone levels in
men seem to have similar effects on CVD risk factors demon-
strating the duality of the mechanism of this hormone [8••,
37••]. These considerations are supported by studies providing
evidence of adverse cardiometabolic consequences in women
with PCOS, a state of relative testosterone excess in women,
such as atherogenic lipid profiles, inflammation, fatty liver
disease, hypertension, diabetes, and coagulopathy [38].
Indeed, in women with obesity, sex hormone-binding
globulin (SHBG) levels are lower—associated with
hyperinsulinemia and increased liver fat—a state related with
higher diabetes risk in women—and further contributing to
higher levels of free testosterone [8••]. Higher insulin levels
resulting from higher insulin resistance contribute to an in-
crease in insulin-mediated ovarian testosterone production in
thecal cells, further contributing to sex hormone imbalance
[39, 40].
Modifiable CVD Risk Factors: Evidence
for the Need for Additional and More
Intensive Risk Reduction Strategies
Among Women
Evidence for the need for additional and more intensive risk
reduction strategies among women can be found in the study
of the Prospective Studies Collaboration and Asia Pacific
Studies Collaboration, where excess mortality risk among
women with diabetes was investigated within other modifi-
able cardiovascular risk factors as BMI, total cholesterol, and
systolic blood pressure compared with men [22]. These risk
factors lead to higher mortality risk in women than in men. In
a secondary analysis of the ADVANCE (Action in Diabetes
and Vascular Disease: Preterax and Diamicron modified re-
lease Controlled Evaluation) trial, smoking contributed to an
increase in CVD mortality in both sexes to a comparable ex-
tent with the exception of some evidence of a greater risk in
women for major coronary events [41•]. Smoking cessation
reduced all-cause mortality risk in both sexes by 30%. Several
studies have indicated that not only might there be more harm
at the same level of risk factors, but that women with diabetes
receive insufficient medical care, leading to a worse CVD risk
factor and management profile [30•, 31•, 33••, 42, 43]. This
would further contribute to CVD outcome differences.
Several such sex differences in CVD risk factors have been
reported [8••, 33••, 42, 43].
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Sex differences in CVD risk factors reported have been
mostly attributed to changes after menopause, including a
higher risk of hypertension in women with diabetes, higher
obesity prevalence aggravating diabetes, and contributing to
additional risk for CVD through inflammatory processes, ec-
topic lipid accumulation, insulin resistance, and hypertension
[33••]. In women with type 2 diabetes, a more adverse cardio-
vascular risk profile has been described with higher metabolic
syndrome prevalence, worse blood pressure control, and
higher HbA1c. In women, hypertension, low physical activity,
and high alcohol intake have been identified to be stronger
predictors for acute myocardial infarction compared with men
[44•]. A recently published meta-analysis of CVOTs found
higher systolic blood pressure (mean difference 1.66 mmHg;
95% CI 0.90, 2.41), LDL-C (0.34 mmol/L; 0.29, 0.39), and
HbA1c (0.11%; 0.09, 0.14; [1.2 mmol/mol 1.0, 1.5]) in the
baseline characteristics of women compared with men partic-
ipating in these trials [13••]. A register study with more than
120,000 patients with T2DM found that those females aged ≥
60 years, when compared with males, were more obese and
more likely to have higher blood pressure and dyslipidemia
rates but lower rates of lipid-lowering medication, worse gly-
cemic control, and a higher risk of retinopathy [45]. In a fur-
ther cross-sectional study investigating men and women with
insulin-treated T2DM aged > 60 years, women were reported
to have higher levels of LDL-C and HDL-C, and higher sys-
tolic and diastolic blood pressures [46]. Furthermore, treat-
ment goals for hypertension were achieved less often bywom-
en, despite comparable glycemia in both sexes. In a study
investigating sex and gender aspects of cardiometabolic risk
in T1DM, similar glycemic control but higher cholesterol in
women, and higher triglyceride in men were reported [47].
Differences in cardiometabolic and CVD risk factors are al-
ready present in prediabetes and continue into diabetes: these
sex differences might start early in life with higher female
subclinical inflammation and coagulopathy evident from early
adulthood [48]. More recent studies found that the highest
relative risk sex difference for CVD events is before 60 years
and highest in women with T2DM at ages 50–60 years [24•].
Differences in lipid storage and body composition driven by
hormonal action seem to play an important role in this puzzle.
Abdominal adiposity does increase in women with aging and
a stronger obesity-diabetes risk association in women has been
reported [8••]. Usually, healthy women feature higher periph-
eral insulin sensitivity, which is reflected in lower absolute
T2DM prevalence compared with men [8••]. This means that
in order to progress to T2DM, healthy women need to gain
more weight than men. Indeed, women do have significantly
higher BMI starting at younger ages when progressing to
T2DM, particularly at younger ages [45]. Moreover, com-
pared with men, women have a more distinct association be-
tween abdominal visceral adipose tissue and insulin resistance
measured by HOMA IR and insulin secretion [49]. This has
been corroborated by a further study demonstrating a higher
risk for acute myocardial infarction in women with higher
waist circumferences and waist-to-hip ratio compared with
men [50•]. In comparison with nulliparous women, BMI
was significantly higher in women with two or more children
(0.6 kg/m2 per child) and significant worse cardiometabolic
parameters with significantly lower HDL cholesterol were ob-
served [51]. Postpartum weight changes were found to be
relevant for cardiometabolic parameters with significantly
higher blood pressure, HOMA-IR, LDL cholesterol, and
apoB in those women who do not lose weight between 3
and 12 months after delivery [52].
Sex Differences in Medication Effects, Side
Effects, CV Risk Reduction Medications,
and Adherence Among People with Type 2
Diabetes
Among participants in the FIELD study, fenofibrate was as-
sociated with greater lipid-lowering effects in women and
demonstrated a 30% reduction of CVD events in women
and 13% in men [53]. Rosuvastatin was associated with great-
er atheroma volume regression (in percent) in women, but a
comparable degree of total atheroma volume regression in
both sexes after 24 months. Atorvastatin has been shown to
have a similar degree of atheroma regression in men and
women [30•]. A higher rate of side effects for statins was
observed in women with increased liver enzymes and myalgia
[54]. In male and female patients with type 2 diabetes, the
benefits of the use of aspirin in secondary prevention of car-
diovascular events were reported [30•]. In a recent meta-
analysis with 12 RCTs including > 34,000 individuals, aspirin
use was found to be effective in primary prevention for
MACE reduction of 11% (RR 0.89 (0.83–0.95)) with no sex
interactions found [55]. During pregnancy, aspirin is recom-
mended for preeclampsia prevention for high-risk women
which includes T1DM and T2DM [56] but whether this inter-
vention reduces later, CVD or CVD risk factors in women
with diabetes is unknown.
Lower medication adherence in women than men has been
reported. It has been postulated that this may be due to lower
self-care activities in women as a result of higher depression
rates, less problem-oriented actions, and fewer problem solv-
ing approaches which have been reported in several studies
[30•]. Furthermore, higher rates of side effects leading to dis-
continuation of therapy were reported. A recently published
meta analysis of CVOTs reported less use of beta-blockers
(RR 0.93; 95% CI 0.88, 0.97), aspirin (0.82; 0.71, 0.95), and
statins (0.90; 0.86, 0.93) in women compared with men but
comparable use of RAAS blockers (RR 1.00; 95% CI 0.99,
1.05) [13••]. Next to the reasons above, health care providers
might underestimate CVD risk in womenwith diabetes, which
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results in less prescribing of CVD protective medication and
thus suboptimal CVD risk factor management.
Sex Differences in CVD Management
Among People with Diabetes
In women with T1DM, adherence to pharmacological in-
tervention and cardio-protective measures was lower in
women with guideline recommendations significantly less
likely to be achieved by women for the target LDL-C
levels, blood pressure, or aspirin prescription [47].
Intensive lifestyle interventions appear to be equally ef-
fective in men and women with diabetes in reducing
weight, improving fitness, and maintaining healthy func-
tioning. Similarly, prevention of progression from im-
paired glucose tolerance to diabetes is equally effective
in men and women with a 37% lower progression rate
to T2DM reported in a systematic review including 12
RCTs [57•]. Meanwhile, the DaQing study in China re-
ported lower CVD mortality in female than male partici-
pants with prediabetes in the 23-year follow-up after life-
style intervention [58]. These results demonstrate the ef-
fectiveness of intensive lifestyle modification in women
with prediabetes and suggest that these approaches might
also help to reduce CVD mortality in women with diabe-
tes. However, this strategy needs to be verified in other
cohorts. Sociocultural aspects cannot be translated easily
to other cohorts and there was a substantial difference in
smoking behavior—a serious CVD risk factor—between
men and women within the DaQing study.
Other Psychological and Socioeconomic
Factors that Might Contribute to Increased
CVD Risk Among Women
Worse metabolic control among women with diabetes is as-
sociated with lower quality of life, higher external dependen-
cy, insomnia, reduced sexual desire, and lower satisfaction
with social support [30•]. Similarly higher diabetes risk
among women has been associated with socioeconomic status
including low education levels, low socioeconomic status in
childhood, and thereafter, high job strain with low decision
latitude, shift work with night shifts causing sleep deprivation
[8••]. In an Austrian health survey including > 13,500 partic-
ipants, only women showed an inverse association between
educational level and diabetes and hypertension, with the
highest risk at the lowest educational level [59]. In both sexes,
overweight/obesity was higher with lower educational levels.
A higher risk of T2DMwas shown in Sweden with increasing
age and among those of lower socioeconomic status which
was accentuated in migrant women [60].
In a meta-analysis of sleep duration in the general
population including > 3,500,000 participants globally,
a U-shaped risk pattern was found for (i) all-cause mor-
tality (RR 1.06 (95% CI, 1.04–1.07) per 1-h reduction
and RR 1.13 (95% CI, 1.11–1.15) per 1-h increment)
and (ii) for cardiovascular mortality (RR 1.06 (95% CI,
1.03–1.08) per 1-h reduction and 1.12 (95% CI, 1.08–
1.16) per 1-h increment). There were no sex differences
and the lowest risk at around a sleep duration of 7 h a
day [61]. Again, in the general population, the Nurses’
Health Study revealed that a sleep duration of less than
5 h was closely linked with a higher incidence of hy-
pertension in younger women [62•]. Findings of a large
study including more than 700,000 people investigating
the relationship of sleep duration and hypertension
across age and sex found that both sexes are prone to
a higher risk of hypertension with short and long
sleeping durations as age increases [63]. The associa-
tions between short sleep duration were stronger among
younger adults and women.
Women with Gestational Diabetes: a Special
Female Population with High Risk
Women with prior GDM are among those with the highest
risk for progression to T2DM and the metabolic syndrome
[31•]. Recently, a Canadian systematic review with pooled
analysis including more than 5,390,000 women and a total
of 101,000 cardiovascular events reported an increased
risk for CVD (RR 1.98, 95% CI 1.57–2.50) up to 10 years
postpartum for women with prior GDM and a subsequent
diagnosis of T2DM [14••]. Interestingly, this risk was also
increased in women with a history of GDM but no pro-
gression to T2DM with an RR of 1.56 (1.04–2.32).
Women with GDM often suffer from hypertensive disor-
ders in pregnancy. A twofold higher risk for CVD com-
pared with women with normotensive pregnancies was
reported in women with hypertensive disorders [64].
Both GDM and hypertensive disorders in pregnancy might
add up to further increased CVD risk in later life.
Intensive lifestyle intervention as reported in the
“Gestational Diabetes’ Effects on Moms “(GEM) study
was able to increase vigorous physical activity and de-
crease weight gain retention by − 0.64 kg (95% CI −
1.13, − 0.14) at 6 months postpartum in women with a
history of GDM compared with usual care [65]. Women
with PCOS are also at an increased risk for the develop-
ment of both T2DM and CVD risk factors with their
higher rates of overweight/obesity including central obe-
sity and dyslipidemia. Although predicted, a higher risk
for CVD mortality has not so far been reported due to
the paucity of population-based long-term studies [66, 67].
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What Can Be Done to Reduce CVD Mortality
Rates Among Women?
It may be possible to reduce CVD mortality rates among
women through a range of strategies (Fig. 1). Firstly, in-
creased awareness of the issue, including sex- and gender-
specific guidelines, may be a starting point, and are consistent
with the move to more personalized care. Such actions have
already commenced in the treatment of those with prevalent
and incident CVD [68]. This has decreased sex disparities
although they are still existing and keep the “Yentl syndrome”
alive (the Yentl Syndrome is the different course of action that
myocardial infarctions usually follow for women than for
men) [69••, 70]. Further work includes further implementation
of standardized protocols, the use of m- and e-health tools to
increase awareness, and the use of artificial intelligence
technology.
Improved management of CVD risk factors among women
is also required, again through awareness, education, guide-
lines, and protocols, and also possibly through earlier man-
agement of hypertension, dyslipidemia, excess weight, and
hyperglycemia. Whether metabolic targets need to be lower
for women is unclear [71].
Further work is needed to address gender differences in
adherence which also appear to be central in the progression
to T2DM and CVD. For example, depression is more preva-
lent in women with prediabetes and diabetes and might ex-
plain some of the differences in treatment adherence [48].
Depression can be aggravated with worse glycemic control,
potentially further contributing to reduced self-management
and thus increasing mortality risk. Improved depression man-
agement in women with diabetes and prediabetes may there-
fore address some of the CVD protection loss.
Evidence for additional and more intensive (some would
say aggressive) treatment to improve CVD outcomes still
needs scientific proof, but several strategies have been shown
to be effective for reducing CVD events before diabetes has
developed including lifestyle interventions in women with
prediabetes, with a history of GDM, hypertensive disorders
in pregnancy, and PCOS [57•, 72, 73••]. Further evidence is
needed to open further opportunities for the prevention of
CVD events among women at risk of diabetes.
Further research into sex and gender differences is impor-
tant to understand the biological basis of these sex disparities
further, how to improve clinical, more personalized care,
alongside studies on how to increase awareness and under-
standing of women, their partners, and health care
professionals.
The associations of sex hormones and glucose metabolism
as well as other hormones such as GLP1 need further investi-
gation, as they seem to have an important role in energy regu-
lation and are involved in beta cell protection [36]. New find-
ings and further research might pave the way for sex-specific
targeted therapeutic modalities, as for example selective estro-
gen receptor modulators in postmenopausal women, GLP-1–
estrogen conjugate pathways or selective ERα activation [36].
Conclusion
We conclude that women need additional and more intensive
cardiovascular risk reduction strategies beyond those current-
ly available to men with diabetes. Women with diabetes have
a higher relative CVD mortality risk, due to the loss of their
“natural” protection with progression to diabetes. Evidence
from recent studies demonstrates that this is especially true
for younger age groups where sex disparities are more preva-
lent and for women with prior GDM. Whether more aggres-
sive strategies are required such as lower metabolic targets,
greater polypharmacy earlier in the disease course is unknown
and warrant urgent trials.
Interventions have commenced [60], including adaptations
to guidelines and protocols, but further work is needed to
address gender differences in adherence through improved
management of co-morbidities, e.g., depression and improved
CVD risk factor management. A key area to be addressed
urgently is the follow-up of women with prior GDM or hy-
pertensive disorders in pregnancy to systematically reduce
progression to T2DM and CVD through evidence-based pro-
grams and services.
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